Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.